Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer - Non Small Cell
- Sponsor
- Our Lady of the Lake Hospital
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Differences in DNA sequence of EGFR gene
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Investigators
Leslie Son
Director of Clinical Research
Our Lady of the Lake Hospital
Eligibility Criteria
Inclusion Criteria
- •18-100 years old
- •Biologically born female
- •Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
- •No cancer diagnosis (Arm 2-health control)
Exclusion Criteria
- •less than 18 years of age
- •Biologically born male
- •Incarcerated at the time of participation
Outcomes
Primary Outcomes
Differences in DNA sequence of EGFR gene
Time Frame: From enrollment to end of data analysis at 6 months
Subjects who have EGFR positive lung cancer will have their gene sequence compared to those that are EGFR negative and do not have lung cancer to look for differences in the sequence.